Craig Jordan

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Brauch Hiltrud; Jordan V Craig
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
Peng Jing; Sengupta Surojeet; Jordan V Craig
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Benson John R; Jatoi Ismail; Keisch Martin; Esteva Francisco J; Makris Andreas; Jordan V Craig
Early breast cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Craig Jordan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Brauch Hiltrud; Jordan V Craig
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
European journal of cancer (Oxford, England : 1990) 2009;45(13):2274-83.
2009: Peng Jing; Sengupta Surojeet; Jordan V Craig
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Anti-cancer agents in medicinal chemistry 2009;9(5):481-99.
2009: Benson John R; Jatoi Ismail; Keisch Martin; Esteva Francisco J; Makris Andreas; Jordan V Craig
Early breast cancer.
Lancet 2009;373(9673):1463-79.
2009: Lewis-Wambi Joan S; Swaby Ramona; Kim Helen; Jordan V Craig
Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.
The Journal of steroid biochemistry and molecular biology 2009;114(1-2):33-9.
2009: Jordan V Craig
A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention.
Cancer research 2009;69(4):1243-54.
2009: Yu Jane J; Robb Victoria A; Morrison Tasha A; Ariazi Eric A; Karbowniczek Magdalena; Astrinidis Aristotelis; Wang Chunrong; Hernandez-Cuebas Lisa; Seeholzer Laura F; Nicolas Emmanuelle; Hensley Harvey; Jordan V Craig; Walker Cheryl L; Henske Elizabeth P
Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(8):2635-40.
2009: Tabuchi Yoko; Matsuoka Junji; Gunduz Mehmet; Imada Takako; Ono Ryoko; Ito Mitsuya; Motoki Takayuki; Yamatsuji Tomoki; Shirakawa Yasuhiro; Takaoka Munenori; Haisa Minoru; Tanaka Noriaki; Kurebayashi Junichi; Jordan V Craig; Naomoto Yoshio
Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
International journal of oncology 2009;34(2):313-9.
2009: Lewis-Wambi Joan S; Jordan V Craig
Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
Breast cancer research : BCR 2009;11(3):206.
2008: Oseni Tawakalitu; Patel Roshani; Pyle Jennifer; Jordan V Craig
Selective estrogen receptor modulators and phytoestrogens.
Planta medica 2008;74(13):1656-65.
2008: Lewis-Wambi Joan S; Cunliffe Heather E; Kim Helen R; Willis Amanda L; Jordan V Craig
Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells.
European journal of cancer (Oxford, England : 1990) 2008;44(12):1770-9.
2008: Jordan V Craig
The rise of raloxifene and the fall of invasive breast cancer.
Journal of the National Cancer Institute 2008;100(12):831-3.
2008: Jordan V Craig
The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):3073-82.
2008: Lu Meiling; Strohecker Anne; Chen Feng; Kwan Toni; Bosman Joshua; Jordan V Craig; Cryns Vincent L
Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3168-76.
2008: Swaby Ramona F; Jordan V Craig
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.
Clinical breast cancer 2008;8(2):124-33.
2008: Jordan V Craig
Tamoxifen: catalyst for the change to targeted therapy.
European journal of cancer (Oxford, England : 1990) 2008;44(1):30-8.
2008: Jordan V Craig; Patel Roshani; Lewis-Wambi Joan S; Swaby Ramona F
By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy.
Breast cancer research : BCR 2008;10 Suppl 4():S16.
2008: Lewis-Wambi Joan S; Kim Helen R; Wambi Chris; Patel Roshani; Pyle Jennifer R; Klein-Szanto Andres J; Jordan V Craig
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Breast cancer research : BCR 2008;10(6):R104.
2008: Sengupta Surojeet; Jordan V Craig
Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Advances in experimental medicine and biology 2008;630():206-19.
2007: Jordan V Craig; O'Malley Bert W
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(36):5815-24.
2007: Jordan V Craig
Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(11):2207-9.
2007: Jordan V Craig
Estrogen receptors in BRCA1-mutant breast cancer: now you see them, now you don't.
Journal of the National Cancer Institute 2007;99(22):1655-7.
2007: Ariazi Eric A; Leitão Andrei; Oprea Tudor I; Chen Bin; Louis Teresa; Bertucci Anne Marie; Sharma Catherine G N; Gill Shaun D; Kim Helen R; Shupp Heather A; Pyle Jennifer R; Madrack Alexis; Donato Anne L; Cheng Dong; Paige James R; Jordan V Craig
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.
Molecular cancer therapeutics 2007;6(11):2817-27.
2007: Jordan V Craig
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.
Steroids 2007;72(13):829-42.
2007: Pannier Angela K; Ariazi Eric A; Bellis Abigail D; Bengali Zain; Jordan V Craig; Shea Lonnie D
Bioluminescence imaging for assessment and normalization in transfected cell arrays.
Biotechnology and bioengineering 2007;98(2):486-97.
2007: Swaby Ramona F; Sharma Catherine G N; Jordan V Craig
SERMs for the treatment and prevention of breast cancer.
Reviews in endocrine & metabolic disorders 2007;8(3):229-39.
2007: Jordan V Craig; Gelber Richard D
Problems with the progesterone receptor in practice?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):1957-9.
2007: Jordan V Craig
SERMs: meeting the promise of multifunctional medicines.
Journal of the National Cancer Institute 2007;99(5):350-6.
2007: Osipo Clodia; Meeke Kathleen; Cheng Dong; Weichel Alyssa; Bertucci Anne; Liu Hong; Jordan V Craig
Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
International journal of oncology 2007;30(2):509-20.
2007: Ariazi Eric A; Kraus Richard J; Farrell Michael L; Jordan V Craig; Mertz Janet E
Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
Molecular cancer research : MCR 2007;5(1):71-85.
2007: Morrow Monica; Jordan V Craig
The current status of breast cancer chemoprevention: a star is born.
Journal of surgical oncology 2007;95(1):4-5.
2007: Jordan V Craig
Chemoprevention of breast cancer with selective oestrogen-receptor modulators.
Nature reviews. Cancer 2007;7(1):46-53.
2007: Jordan V Craig; Brodie Angela M H
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Steroids 2007;72(1):7-25.
2007: Jordan V C
Beyond raloxifene for the prevention of osteoporosis and breast cancer.
British journal of pharmacology 2007;150(1):3-4.
2007: Patel Roshani R; Sharma Catherine G N; Jordan V Craig
Optimizing the antihormonal treatment and prevention of breast cancer.
Breast cancer (Tokyo, Japan) 2007;14(2):113-22.
2006: Chatterton Robert T; Zujewski JoAnne; Mateo Esnar T; Eng-Wong Jennifer; Jordan V Craig
Effect of raloxifene on salivary sex steroid concentrations in premenopausal women.
The Journal of endocrinology 2006;191(3):599-604.
2006: Cordera Fernando; Jordan V Craig
Steroid receptors and their role in the biology and control of breast cancer growth.
Seminars in oncology 2006;33(6):631-41.
2006: Dahlman-Wright Karin; Cavailles Vincent; Fuqua Suzanne A; Jordan V Craig; Katzenellenbogen John A; Korach Kenneth S; Maggi Adriana; Muramatsu Masami; Parker Malcolm G; Gustafsson Jan-Ake
International Union of Pharmacology. LXIV. Estrogen receptors.
Pharmacological reviews 2006;58(4):773-81.
2006: Ariazi Eric A; Lewis-Wambi Joan S; Gill Shaun D; Pyle Jennifer R; Ariazi Jennifer L; Kim Helen R; Sharma Catherine G N; Cordera Fernando; Shupp Heather A; Li Tianyu; Jordan V Craig
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.
The Journal of steroid biochemistry and molecular biology 2006;102(1-5):128-38.
2006: Jordan V Craig
Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2909-13.
2006: Liu Hong; Cheng Dong; Weichel Alyssa K; Osipo Clodia; Wing Laura K; Chen Bin; Louis Teresa E; Jordan V Craig
Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
International journal of oncology 2006;29(5):1237-46.
2006: Liu Shengxi; Abdelrahim Maen; Khan Shaheen; Ariazi Eric; Jordan V Craig; Safe Stephen
Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells.
Biological chemistry 2006;387(9):1209-13.
2006: Jordan V Craig
The science of selective estrogen receptor modulators: concept to clinical practice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5010-3.
2006: Jordan V Craig
A STAR is born.
Oncology (Williston Park, N.Y.) 2006;20(9):1126.
2006: Nam Jeong-Seok; Kang Mi-Jin; Suchar Adam M; Shimamura Takeshi; Kohn Ethan A; Michalowska Aleksandra M; Jordan V Craig; Hirohashi Setsuo; Wakefield Lalage M
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.
Cancer research 2006;66(14):7176-84.
2006: Vogel Victor G; Costantino Joseph P; Wickerham D Lawrence; Cronin Walter M; Cecchini Reena S; Atkins James N; Bevers Therese B; Fehrenbacher Louis; Pajon Eduardo R; Wade James L; Robidoux André; Margolese Richard G; James Joan; Lippman Scott M; Runowicz Carolyn D; Ganz Patricia A; Reis Steven E; McCaskill-Stevens Worta; Ford Leslie G; Jordan V Craig; Wolmark Norman;
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA : the journal of the American Medical Association 2006;295(23):2727-41.
2006: Jordan V Craig; Knudson Alfred G
Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective.
Oncology (Williston Park, N.Y.) 2006;20(6):553-62; discussion 567-8, 573, 577.
2006: Jordan V Craig
Pak up your breast tumor--and grow!
Journal of the National Cancer Institute 2006;98(10):657-9.
2006: O'Regan Ruth M; Osipo Clodia; Ariazi Eric; Lee Eun Sook; Meeke Kathleen; Morris Caroline; Bertucci Anne; Sarker Mohammad A B; Grigg Ronald; Jordan V Craig
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2255-63.
2006: Abdelrahim Maen; Ariazi Eric; Kim Kyounghyun; Khan Shaheen; Barhoumi Rola; Burghardt Robert; Liu Shengxi; Hill Denise; Finnell Richard; Wlodarczyk Bogdan; Jordan V Craig; Safe Stephen
3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha.
Cancer research 2006;66(4):2459-67.
2006: Jordan V Craig
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer.
British journal of pharmacology 2006;147 Suppl 1():S269-76.
2006: Ariazi Eric A; Ariazi Jennifer L; Cordera Fernando; Jordan V Craig
Estrogen receptors as therapeutic targets in breast cancer.
Current topics in medicinal chemistry 2006;6(3):181-202.
2006: Ariazi Eric A; Jordan V Craig
Estrogen-related receptors as emerging targets in cancer and metabolic disorders.
Current topics in medicinal chemistry 2006;6(3):203-15.
2006: Schafer Jennifer MacGregor; Jordan V Craig
Models of hormone resistance in vitro and in vivo.
Methods in molecular medicine 2006;120():453-64.
2005: Lewis Joan S; Meeke Kathleen; Osipo Clodia; Ross Eric A; Kidawi Noman; Li Tianyu; Bell Eric; Chandel Navdeep S; Jordan V Craig
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
Journal of the National Cancer Institute 2005;97(23):1746-59.
2005: Levenson Anait S; Thurn Kenneth E; Simons Laura A; Veliceasa Dorina; Jarrett Jennifer; Osipo Clodia; Jordan V Craig; Volpert Olga V; Satcher Robert L; Gartenhaus Ronald B
MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.
Cancer research 2005;65(23):10651-6.
2005: Jordan V Craig; Lewis Joan S; Osipo Clodia; Cheng Dong
The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.
Breast (Edinburgh, Scotland) 2005;14(6):624-30.
2005: Lewis Joan S; Jordan V Craig
Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Mutation research 2005;591(1-2):247-63.
2005: Park Woo-Chan; Liu Hong; Macgregor Schafer Jennifer; Jordan V Craig
Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells.
International journal of oncology 2005;27(5):1459-66.
2005: Osipo Clodia; Meeke Kathleen; Liu Hong; Cheng Dong; Lim Sherry; Weichel Alyssa; Jordan V Craig
Trastuzumab therapy for tamoxifen-stimulated endometrial cancer.
Cancer research 2005;65(18):8504-13.
2005: Chen Bin; Gajdos Csaba; Dardes Rita; Kidwai Noman; Johnston Stephen R D; Dowsett Mitchell; Jordan V Craig
Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
International journal of oncology 2005;27(2):327-35.
2005: Chatterton Robert T; Mateo Esnar T; Hou Nanjiang; Rademaker Alfred W; Acharya Simbi; Jordan V Craig; Morrow Monica
Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women.
The Journal of endocrinology 2005;186(1):77-84.
2005: Jordan V Craig
Medroxyprogesterone acetate and metastases: of mice and (wo)men.
Journal of the National Cancer Institute 2005;97(9):619-21.
2005: Jordan V Craig
Chemoprevention in the 21st century: is a balance best or should women have no estrogen at all?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(8):1598-600.
2005: Kamradt Merideth C; Lu Meiling; Werner Michael E; Kwan Toni; Chen Feng; Strohecker Anne; Oshita Shayna; Wilkinson John C; Yu Chunjiang; Oliver Patsy G; Duckett Colin S; Buchsbaum Donald J; LoBuglio Albert F; Jordan V Craig; Cryns Vincent L
The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3.
The Journal of biological chemistry 2005;280(12):11059-66.
2005: Lewis J S; Osipo C; Meeke K; Jordan V C
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.
The Journal of steroid biochemistry and molecular biology 2005;94(1-3):131-41.
2005: Osipo Clodia; Gajdos Csaba; Cheng Dong; Jordan V Craig
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
The Journal of steroid biochemistry and molecular biology 2005;93(2-5):249-56.
2005: Lu Meiling; Kwan Toni; Yu Chunjiang; Chen Feng; Freedman Bethany; Schafer Jennifer M; Lee Eun-Jig; Jameson J Larry; Jordan V Craig; Cryns Vincent L
Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.
The Journal of biological chemistry 2005;280(8):6742-51.
2005: Lewis-Wambi Joan S; Jordan V Craig
Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Breast disease 2005;24():93-105.
2004: Osipo Clodia; Liu Hong; Meeke Kathleen; Jordan V Craig
The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death.
Experimental biology and medicine (Maywood, N.J.) 2004;229(8):722-31.
2004: Tchou Julia; Hou Nanjiang; Rademaker Alfred; Jordan V Craig; Morrow Monica
Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Cancer 2004;100(9):1800-6.
2004: Dougherty Michele K; Schumaker Lisa M; Jordan V Craig; Welshons Wade V; Curran Edward M; Ellis Matthew J; El-Ashry Dorraya
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer.
Cancer biology & therapy 2004;3(5):460-7.
2004: Pearce Sandra Timm; Jordan V Craig
The biological role of estrogen receptors alpha and beta in cancer.
Critical reviews in oncology/hematology 2004;50(1):3-22.
2004: Pearce Sandra Timm; Liu Hong; Radhakrishnan Ishwar; Abdelrahim Maen; Safe Stephen; Jordan V Craig
Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha.
Cancer research 2004;64(8):2889-97.
2004: Gehm Barry D; Levenson Anait S; Liu Hong; Lee Eun-Jig; Amundsen Beth M; Cushman Mark; Jordan V Craig; Jameson J Larry
Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2.
The Journal of steroid biochemistry and molecular biology 2004;88(3):223-34.
2004: Jordan V Craig
Selective estrogen receptor modulation: concept and consequences in cancer.
Cancer cell 2004;5(3):207-13.
2004: Jordan V Craig
Aromatase inhibitors that regulate estrogen target tissues selectively?
Bone 2004;34(3):372-5.
2003: Jordan V C; Osipo C; Schafer J MacGregor; Fox J E; Cheng Dong; Liu Hong
Changing role of the oestrogen receptor in the life and death of breast cancer cells.
Breast (Edinburgh, Scotland) 2003;12(6):432-41.
2003: Bentrem David; Fox Jennifer E; Pearce Sandra Timm; Liu Hong; Pappas Sam; Kupfer David; Zapf James W; Jordan V Craig
Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens.
Cancer research 2003;63(21):7490-6.
2003: Osipo Clodia; Gajdos Csaba; Liu Hong; Chen Bin; Jordan V Craig
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Journal of the National Cancer Institute 2003;95(21):1597-608.
2003: Liu Hong; Lee Eun-Sook; Gajdos Csaba; Pearce Sandra Timm; Chen Bin; Osipo Clodia; Loweth Jessica; McKian Kevin; De Los Reyes Alexander; Wing Laura; Jordan V Craig
Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
Journal of the National Cancer Institute 2003;95(21):1586-97.
2003: Jensen Elwood V; Jordan V Craig
The estrogen receptor: a model for molecular medicine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):1980-9.
2003: Jordan V Craig; Morrow Monica
Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Journal of the National Cancer Institute 2003;95(9):683-4; author reply 684-5.
2003: de Lima G R; Facina G; Shida J Y; Chein M B C; Tanaka P; Dardes R C; Jordan V C; Gebrim L H
Effects of low dose tamoxifen on normal breast tissue from premenopausal women.
European journal of cancer (Oxford, England : 1990) 2003;39(7):891-8.
2003: Mishra Sandip K; Mazumdar Abhijit; Vadlamudi Ratna K; Li Feng; Wang Rui-An; Yu Wei; Jordan V Craig; Santen Richard J; Kumar Rakesh
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions.
The Journal of biological chemistry 2003;278(21):19209-19.
2003: Levenson Anait S; Gehm Barry D; Pearce Sandra Timm; Horiguchi Jun; Simons Laura A; Ward James E; Jameson J Larry; Jordan V Craig
Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha.
International journal of cancer. Journal international du cancer 2003;104(5):587-96.
2003: Jordan V Craig
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Journal of medicinal chemistry 2003;46(7):1081-111.
2003: Jordan V Craig
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.
Journal of medicinal chemistry 2003;46(6):883-908.
2003: Jordan V Craig
Is tamoxifen the Rosetta stone for breast cancer?
Journal of the National Cancer Institute 2003;95(5):338-40.
2003: Jordan V Craig
Tamoxifen: a most unlikely pioneering medicine.
Nature reviews. Drug discovery 2003;2(3):205-13.
2003: Pearce Sandra Timm; Liu Hong; Jordan V Craig
Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12.
The Journal of biological chemistry 2003;278(9):7630-8.
2003: Jordan V Craig
The ups and downs of the estrogen receptor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):3-4.
2003: Gradishar William J; Jordan V Craig
Advances in endocrine therapy for the treatment and prevention of breast cancer.
Cancer chemotherapy and biological response modifiers 2003;21():211-22.
2003: Jordan V Craig; Ponder Bruce A J
Introducing a new section to Breast Cancer Research: endocrinology and hormone therapy.
Breast cancer research : BCR 2003;5(6):281-3.
2002: Bentrem D J; Jordan V C
Antiestrogens: the past and the future.
Zentralblatt für Gynäkologie 2002;124(12):551-8.
2002: Schafer Jennifer MacGregor; Bentrem David J; Takei Hiroyuki; Gajdos Csaba; Badve Sunil; Jordan V Craig
A mechanism of drug resistance to tamoxifen in breast cancer.
The Journal of steroid biochemistry and molecular biology 2002;83(1-5):75-83.
2002: Chatterton Robert T; Lydon John P; Mehta Rajendra G; Mateo Esnar T; Pletz Ashley; Jordan V Craig
Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro.
Cancer letters 2002;188(1-2):47-52.
2002: Levenson A S; Kliakhandler I L; Svoboda K M; Pease K M; Kaiser S A; Ward J E; Jordan V C
Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha.
British journal of cancer 2002;87(4):449-56.
2002: Jordan V Craig; Liu Hong; Dardes Rita
Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death.
Journal of the National Cancer Institute 2002;94(15):1173; author reply 1173-5.
2002: Levenson Anait S; Svoboda Kristen M; Pease Katherine M; Kaiser Scott A; Chen Bin; Simons Laura A; Jovanovic Borko D; Dyck Patricia A; Jordan V Craig
Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
Cancer research 2002;62(15):4419-26.
2002: Dardes Rita C; O'Regan Ruth M; Gajdos Csaba; Robinson Simon P; Bentrem David; De Los Reyes Alex; Jordan V Craig
Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1995-2001.
2002: Dardes R C; Schafer J MacGregor; Pearce S Timm; Osipo C; Chen B; Jordan V C
Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Gynecologic oncology 2002;85(3):498-506.
2002: Jordan V Craig
The secrets of selective estrogen receptor modulation: cell-specific coregulation.
Cancer cell 2002;1(3):215-7.
2002: O'Regan Ruth M; Jordan V Craig
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.
The lancet oncology 2002;3(4):207-14.
2002: Liu Hong; Park Woo-Chan; Bentrem David J; McKian Kevin P; Reyes Alexander De Los; Loweth Jessica A; Schafer Jennifer MacGregor; Zapf James W; Jordan V Craig
Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
The Journal of biological chemistry 2002;277(11):9189-98.
2002: O'Regan Ruth M; Gajdos Csaba; Dardes Rita C; De Los Reyes Alex; Park Woochan; Rademaker Alfred W; Jordan V Craig
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.
Journal of the National Cancer Institute 2002;94(4):274-83.
2002: Park Woo-Chan; Jordan V Craig
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Trends in molecular medicine 2002;8(2):82-8.
2002: Bentrem David J; Jordan V Craig
Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
Current opinion in obstetrics & gynecology 2002;14(1):5-12.
2002: Gajdos Csaba; Jordan V Craig
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Clinical breast cancer 2002;2(4):272-81.
2002: Jordan V Craig; Morrow Monica
Chemoprevention of breast cancer: a model for change.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):1-3.
2002: Gradishar William J; Jordan V Craig
The evolving role of endocrine therapy for the treatment and prevention of breast cancer.
Cancer chemotherapy and biological response modifiers 2002;20():227-38.
2002: Pappas Sam G; Jordan V Craig
Chemoprevention of breast cancer: current and future prospects.
Cancer metastasis reviews 2002;21(3-4):311-21.
2002: Jordan V Craig
A new day dawns: women without oestrogen or is a balance best?
Breast cancer research : BCR 2002;4(6):218-21.
2002: Takei Hiroyuki; Lee Eun-Sook; Jordan V Craig
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer.
Breast cancer (Tokyo, Japan) 2002;9(1):39-42.
2001: Jordan V C
Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
Annals of the New York Academy of Sciences 2001;952():60-72.
2001: Jordan V C
The past, present, and future of selective estrogen receptor modulation.
Annals of the New York Academy of Sciences 2001;949():72-9.
2001: Dardes R C; Bentrem D; O'Regan R M; Schafer J M; Jordan V C
Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):4149-55.
2001: Pappas S G; Jordan V C
Raloxifene for the treatment and prevention of breast cancer?
Expert review of anticancer therapy 2001;1(3):334-40.
2001: Chisamore M J; Ahmed Y; Bentrem D J; Jordan V C; Tonetti D A
Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3156-65.
2001: Jordan V C; Gapstur S; Morrow M
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Journal of the National Cancer Institute 2001;93(19):1449-57.
2001: Jordan V C; Schafer J M; Levenson A S; Liu H; Pease K M; Simons L A; Zapf J W
Molecular classification of estrogens.
Cancer research 2001;61(18):6619-23.
2001: Schafer J M; Lee E S; Dardes R C; Bentrem D; O'Regan R M; De Los Reyes A; Jordan V C
Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2505-12.
2001: Jordan V C
Selective estrogen receptor modulation: a personal perspective.
Cancer research 2001;61(15):5683-7.
2001: MacGregor Schafer J; Liu H; Levenson A S; Horiguchi J; Chen Z; Jordan V C
Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.
The Journal of steroid biochemistry and molecular biology 2001;78(1):41-50.
2001: Fournier D B; Chisamore M; Lurain J R; Rademaker A W; Jordan V C; Tonetti D A
Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer.
Gynecologic oncology 2001;81(3):366-72.
2001: Liu H; Lee E S; Deb Los Reyes A; Zapf J W; Jordan V C
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Cancer research 2001;61(9):3632-9.
2001: Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Endocrinology 2001;142(2):838-46.
2001: Levenson A S; MacGregor Schafer J I; Bentrem D J; Pease K M; Jordan V C
Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351.
The Journal of steroid biochemistry and molecular biology 2001;76(1-5):61-70.
2001: Cauley J A; Norton L; Lippman M E; Eckert S; Krueger K A; Purdie D W; Farrerons J; Karasik A; Mellstrom D; Ng K W; Stepan J J; Powles T J; Morrow M; Costa A; Silfen S L; Walls E L; Schmitt H; Muchmore D B; Jordan V C; Ste-Marie L G
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Breast cancer research and treatment 2001;65(2):125-34.
2001: Bentrem D J; O'Regan R M; Jordan V C
New strategies for the treatment of breast cancer.
Breast cancer (Tokyo, Japan) 2001;8(4):265-74.
2001: Gradishar W J; Jordan V C
The evolving role of endocrine therapy for treatment and prevention of breast cancer.
Cancer chemotherapy and biological response modifiers 2001;19():215-36.
2001: O'Regan R M; Jordan V C
Chemoprevention of breast cancer.
Cancer treatment and research 2001;106():137-54.
2000: Lee E S; Schafer J M; Yao K; England G; O'Regan R M; De Los Reyes A; Jordan V C
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4893-9.
2000: Jordan V C
Progress in the prevention of breast cancer: concept to reality.
The Journal of steroid biochemistry and molecular biology 2000;74(5):269-77.
2000: Schafer J M; Lee E S; O'Regan R M; Yao K; Jordan V C
Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4373-80.
2000: Hozumi Y; Kawano M; Jordan V C
In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen.
European journal of endocrinology / European Federation of Endocrine Societies 2000;143(3):427-30.
2000: MacGregor Schafer J; Liu H; Bentrem D J; Zapf J W; Jordan V C
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
Cancer research 2000;60(18):5097-105.
2000: Tonetti D A; Chisamore M J; Grdina W; Schurz H; Jordan V C
Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.
British journal of cancer 2000;83(6):782-91.
2000: Takei H; Lee E S; Cisneros A; Jordan V C
Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice.
Cancer letters 2000;155(2):129-35.
2000: Yao K; Lee E S; Bentrem D J; England G; Schafer J I; O'Regan R M; Jordan V C
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):2028-36.
2000: Dardes R D; Horiguchi J; Jordan V C
A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer.
International journal of oncology 2000;16(1):25-30.
1999: Levenson A S; Jordan V C
Selective oestrogen receptor modulation: molecular pharmacology for the millennium.
European journal of cancer (Oxford, England : 1990) 1999;35(14):1974-85.
1999: Levenson A S; Jordan V C
Selective oestrogen receptor modulation: molecular pharmacology for the millennium.
European journal of cancer (Oxford, England : 1990) 1999;35(12):1628-39.
1999: Tonetti D A; Jordan V C
The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.
Journal of mammary gland biology and neoplasia 1999;4(4):401-13.
1999: Schafer J I; Liu H; Tonetti D A; Jordan V C
The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
Cancer research 1999;59(17):4308-13.
1999: Cummings S R; Eckert S; Krueger K A; Grady D; Powles T J; Cauley J A; Norton L; Nickelsen T; Bjarnason N H; Morrow M; Lippman M E; Black D; Glusman J E; Costa A; Jordan V C
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA : the journal of the American Medical Association 1999;281(23):2189-97.
1999: Jordan V C
Estrogen receptor as a target for the prevention of breast cancer.
The Journal of laboratory and clinical medicine 1999;133(5):408-14.
1999: Bentrem D J; Jordan V C
Targeted antiestrogens for the prevention of breast cancer.
Oncology research 1999;11(9):401-7.
1998: O'Regan R M; Cisneros A; England G M; MacGregor J I; Muenzner H D; Assikis V J; Bilimoria M M; Piette M; Dragan Y P; Pitot H C; Chatterton R; Jordan V C
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Journal of the National Cancer Institute 1998;90(20):1552-8.
1998: Levenson A S; Kwaan H C; Svoboda K M; Weiss I M; Sakurai S; Jordan V C
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
British journal of cancer 1998;78(1):88-95.
1998: Dragan Y P; Shimel R J; Bahnub N; Sattler G; Vaughan J R; Jordan V C; Pitot H C
Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats.
Toxicological sciences : an official journal of the Society of Toxicology 1998;43(2):129-38.
1998: MacGregor J I; Jordan V C
Basic guide to the mechanisms of antiestrogen action.
Pharmacological reviews 1998;50(2):151-96.
1998: Levenson A S; Jordan V C
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
Cancer research 1998;58(9):1872-5.
1998: England G M; Bilimoria M M; Chen Z; Assikis V J; Muenzner H D; Jordan V C
Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor.
International journal of oncology 1998;12(5):981-6.
1998: Levenson A S; Svoboda K M; Kwaan H C; Jordan V C
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
Cancer letters 1998;125(1-2):215-20.
1998: O'Regan R M; England G M; Macgregor J I; Yao K A; Muenzner H D; Takei H; Jordan V C
Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy.
Breast cancer (Tokyo, Japan) 1998;5(3):211-7.
1998: Bilimoria M M; Jordan V C
The duration of adjuvant tamoxifen therapy.
Cancer treatment and research 1998;94():181-93.
1997: Li D; Dragan Y; Jordan V C; Wang M; Pitot H C
Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
Cancer research 1997;57(8):1438-41.
1997: England G M; Jordan V C
Pure antiestrogens as a new therapy for breast cancer.
Oncology research 1997;9(8):397-402.
1997: Pink J J; Fritsch M; Bilimoria M M; Assikis V J; Jordan V C
Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line.
British journal of cancer 1997;75(1):17-27.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Craig Jordan

Research Profile (preview)

Disorders

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Craig Jordan (preview)

All Publications